Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
Authors:
Open Access
- 6 November 2013
- journal article
- review article
- Published by Hindawi Limited in ISRN Cardiology
- Vol. 2013, 1-8
Abstract
Context. Whether angiotensin converting-enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB) are useful in high risk patients without heart failure is unclear. We perform a meta-analysis of prospective randomized placebo-controlled ACEI or ARB trials studying patients with a combination of risk factors to assess treatment impact on all cause mortality, cardiovascular mortality, nonfatal myocardial infarction (MI) and stroke. Method. A PubMed search was made for placebo-controlled trials recruiting at least 1,200 high risk patients randomized to either ACEI or ARB, with follow-up of at least 2 years. Meta-analysis was performed using the RevMan 5 program and Mantel-Haenszel analysis was done with a fixed effects model. Results. Ten trials recruiting 77,633 patients were reviewed. All cause mortality was significantly reduced by ACEI (RR 0.89; ), but not by ARB treatment (RR 1.00; ). Cardiovascular mortality and nonfatal MI were also reduced in the ACEI trials but not with ARB therapy. Stroke was significantly reduced in the ACEI trials (RR 0.75; ) and more modestly reduced in the ARB trials (RR 0.90; ). Conclusion. ACEI treatment reduced stroke, nonfatal MI, cardiovascular and total mortality in high risk patients, while ARB modestly reduced stroke with no effect on nonfatal MI, cardiovascular and total mortality.
Keywords
This publication has 37 references indexed in Scilit:
- Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patientsEuropean Heart Journal, 2012
- Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular EventsNew England Journal of Medicine, 2010
- Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBsAmerican Journal of Cardiovascular Drugs, 2009
- Telmisartan to Prevent Recurrent Stroke and Cardiovascular EventsNew England Journal of Medicine, 2008
- RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyThe Lancet, 2007
- Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2004
- More Hype Than HOPEHypertension, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Comparative Effects of Ramipril on Ambulatory and Office Blood PressuresHypertension, 2001